Onclive reports on recent data from the CheckMate-214 trial. They write that nivolumab (Opdivo) combined with low-dose ipilimumab (Yervoy) continued to demonstrate strong responses and a survival benefit at 30 months follow-up as a frontline treatment for patients with intermediate and poor risk advanced renal cell carcinoma. Onclive notes a 30-month overall survival (OS) rate of 60% with the immunotherapy combination vs. 47% with sunitinib in the intermediate and poor risk population (HR, 0.66; 95% CI, 0.54-0.80; P <.0001). The objective response rates (ORRs) were 42% versus 29% (P = .0001), respectively, including complete response (CR) rates of 11% versus 1%. Among the responders, 52% of patients receiving nivolumab/ipilimumab had a response duration ≥18 months compared with 28% of patients on the TKI arm. Follow the link below for the entire Onclive report.